Targeting vascular endothelial growth factor in renal cell carcinoma

Tumor Biology

Volumn 30, Issue 5-6, 2009, Pages 292-299

  Patel, Nilay S ^a   Muneer, Asif ^c   Blick, Christopher ^a   Arya, Manit ^c   Harris, Adrian L ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Clear cell renal cell carcinoma; Hypoxia inducible factors; Renal cell carcinoma; Vascular endothelial growth factor; Von Hippel Lindau gene

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INTERLEUKIN 2; PLACEBO; PLACENTAL GROWTH FACTOR; RECOMBINANT INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; BLEEDING; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; HYPOXIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; MOLECULAR BIOLOGY; MUCOSA INFLAMMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; PROTEINURIA; RASH; SHORT SURVEY; SIGNAL TRANSDUCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TUMOR VASCULARIZATION;

EID: 70450176108     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000260241     Document Type: Short Survey

References (49)

1. National Cancer Institute of the US Natioanal Institute of Health, Kidney Cancer Statistics. www.cancer.gov/cancertopics/types/ kidney.
2. Lightfoot N, Conlon M, Kreiger N, Bissett R, Desai M, Warde P, Prichard HM: Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol 2000; 37: 521-527.
3. Javidan J, Stricker HJ, Tamboli P, Amin MB, Peabody JO, Deshpande A, Menon M: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999; 162: 1277-1281.
4. Tsui KH, Shvarts O, Smith RB, Figlin RA, De Kernion JB, Belldegrun A: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-1095.
5. McDermott DF, Rini BI: Immunotherapy for metastatic renal cell carcinoma. BJU Int 2007; 99(5 pt B):1282-1288.
6. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al: Identification of the von Hippel- Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
7. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
8. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor- suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704. (Pubitemid 24311875)
9. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
10. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
11. Bruick RK, McKnight SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-1340.
12. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O 2 -regulated prolyl hydroxylation. Science 2001; 292: 468-472.
13. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
14. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
15. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
16. Cross MJ, Claesson-Welsh L: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201-207.
17. Rossant J, Howard L: Signaling pathways in vascular development. Annu Rev Cell Dev Biol 2002; 18: 541-573.
18. Ruhrberg C: Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 2003; 25: 1052-1060.
19. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor-β1 , platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
20. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281-5285. (Pubitemid 27516364)
21. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL: Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000; 60: 3088-3095.
22. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL: Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel- Lindau gene mutation. Cancer Res 2002; 62: 2957-2961.
23. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65: 8690-8697.
24. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM: Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas. J Urol 2003; 170: 588-592.
25. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004; 93: 291-296.
26. Yoshino S, Kato M, Okada K: Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int J Urol 1998; 5: 119-123.
27. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297-302.
28. Yildiz E, Ayan S, Goze F, Gokce G, Gultekin EY: Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma. BJU Int 2008; 101: 758-764.
29. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
30. Rowe DH, Huang J, Kayton ML, et al: Anti- VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000; 35: 30-32.
31. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
32. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
33. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, Kliche S, Fellbrich G, Ballmer-Hofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P: Role of PlGF in the intra- and intermolecular cross-talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943.
34. Holash J, Davis S, Papadopoulos N, et al: VEGFTrap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398.
35. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
36. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. (Pubitemid 46630627)
37. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
38. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
39. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
40. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
41. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
42. Rini B: Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008; 14: 1286-1290.
43. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122-127.
44. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
45. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
46. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. (Pubitemid 46849157)
47. Ljungberg B, Hanbury DC, Kuczyk MA, et al: Renal cell carcinoma guideline. Eur Urol 2007; 51: 1502-1510.
48. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Available at: http:// www.nccn.org. (accessed August 2008).
49. National Institute of Health and Clinical Excellence (NICE): Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation. www.nice. org.uk. (accessed March 2009).